Dr. Christiansen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2405 Shadelands Dr
Ste 300
Walnut Creek, CA 94598Phone+1 925-939-8585
Education & Training
- University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 1988 - 1990
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1985 - 1988
- Case Western Reserve University School of MedicineClass of 1985
Certifications & Licensure
- CA State Medical License 1988 - 2025
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism Start of enrollment: 2011 Sep 01
- A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use Start of enrollment: 2011 Nov 01
Publications & Presentations
PubMed
- 79 citationsDesign, development, and evaluation of a novel microneedle array-based continuous glucose monitorArvind N. Jina, Michael J. Tierney, Janet A. Tamada, Scott McGill, Shashi Desai
Journal of Diabetes Science and Technology. 2014-03-06 - 86 citationsInvestigation of the Accuracy of 18 Marketed Blood Glucose Monitors.David C. Klonoff, Joan Lee Parkes, Boris Kovatchev, David Kerr, Wendy C. Bevier
Diabetes Care. 2018-05-31 - 20 citationsA New, Wireless-enabled Blood Glucose Monitoring System That Links to a Smart Mobile Device: Accuracy and User Performance Evaluation.Mark P. Christiansen, Carmine Greene, Scott Pardo, Mary Ellen Warchal-Windham, Bern Harrison
Journal of Diabetes Science and Technology. 2017-02-01
Press Mentions
- Abbott, Medtronic Go Head-to-Head at ADA ConferenceJune 15th, 2020
- Senseonics Announces First Study Participant Implanted in the U.S. As Part of the PROMISE 180-Day Sensor Clinical Study and the Submission of Key PMA Supplements to the FDA to Advance Current 90-Day ProductJanuary 3rd, 2019
- Senseonics Maakt Uitstekende Nauwkeurigheidsresultaten Bekend Uit Hoofdstudie Eversense CGM-Systeem in VSAugust 10th, 2016
- Join now to see all
Grant Support
- Hepatic Insulin Resistance Associated With The Use Of PINational Center For Research Resources2000–2002
- Effects Of Etiocholanedione On Hepatic Metabolism &Insulin ResistancNational Center For Research Resources1999–2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: